2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106246
    Pruvanserin 443144-26-1 99.54%
    Pruvanserin (EMD 281014 free base) is a selective 5-HT2A receptor antagonist. Pruvanserin alleviates tactile allodynia in diabetic rats. Pruvanserin can also be used for research of insomnia.
    Pruvanserin
  • HY-106405
    Nebicapone 274925-86-9 99.89%
    Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease.
    Nebicapone
  • HY-107532
    N-Nonyldeoxynojirimycin 81117-35-3 ≥99.0%
    N-Nonyldeoxynojirimycin (NN-DNJ) is a deoxynojirimycin derivative with a hydrophobic long chain. N-Nonyldeoxynojirimycin is an orally active inhibitor of acid α-glucosidase (IC50: 0.42 μM) and α-1,6-glucosidase (IC50: 8.4 μM). N-Nonyldeoxynojirimycin has activities of inhibiting glycogen breakdown, anti-virus and anti-tumor. N-Nonyldeoxynojirimycin also has insecticidal effects, with an LD50 of 5 mM for adults of Bemisia tabaci.
    N-Nonyldeoxynojirimycin
  • HY-108972
    SQ 29548 98672-91-4 ≥99.0%
    SQ 29548 is a selective thromboxane-prostanoid (TP) receptor antagonist.
    SQ 29548
  • HY-113013
    Hydroxypyruvic acid 1113-60-6 99.77%
    Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.
    Hydroxypyruvic acid
  • HY-117516
    SR10067 1380548-02-6 ≥99.0%
    SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders.
    SR10067
  • HY-117772
    FSC231 1215849-96-9 99.51%
    FSC231 is a PSD‐95/DLG/ZO‐1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects.
    FSC231
  • HY-121006
    Biguanide 56-03-1 98.07%
    Biguanide is an orally active antihyperglycemic agent. Biguanide inhibits mitochondrial ATP production, activates the LKB1-AMPK signaling pathway, and damages the energy homeostasis. Biguanide enhances insulin-receptor activation and downstream signaling. Biguanide exhibits potential in ameliorating the type 2 diabetes and the insulin-associated cancers.
    Biguanide
  • HY-122940
    Precocene II 644-06-4 99.98%
    Precocene II (Ageratochromene) is a plant larva hormone antagonists that inhibits the biosynthesis of juvenile hormone. Precocene II inhibits corpora allata function and downregulates juvenile hormone levels, while exerting multiple effects including inducing precocious metamorphosis, forming macropterous morphs, inhibiting ovarian growth, producing cytotoxicity, disrupting insect development, and causing sterility and kidney damage. Precocene II blocks normal nymphal development, causes renal tubular damage and increases blood urea nitrogen levels, and also blocks juvenile hormone biosynthesis in vitro. Precocene II undergoes oxidative metabolism catalyzed by NADPH-dependent monooxygenase to generate a variety of metabolites. Precocene II can be applied in studies related to insect growth regulation and nephrotoxicity.
    Precocene II
  • HY-123984
    LTβR-IN-1 2189366-77-4 99.79%
    LTβR-IN-1 (Compound 919278) is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1 regulates the NF-kB signaling pathway IN a ligand-independent manner.
    LTβR-IN-1
  • HY-124097
    HNMPA-(AM)3 120944-03-8 98.04%
    HNMPA-(AM)3 is a cell-permeable and selective insulin receptor tyrosine kinase inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis. HNMPA-(AM)3 is also effective in inhibiting ecdysteroid production (IC50=14.2 μM) and insulin receptor activity (IC50 is 14.2 μM and 200 μM in mosquitoes and mammals, respectively).
    HNMPA-(AM)3
  • HY-124700
    LYPLAL1-IN-1 1966129-74-7 99.9%
    LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8+ T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors.
    LYPLAL1-IN-1
  • HY-126535
    Magnoloside B 116872-05-0 99.69%
    Magnoloside B is an α-glucosidase inhibitor (IC50=0.69 mM), which can be obtained from Magnolia officinalis stem bark. Magnoloside B shows moderate inhibitory activity against MGC-803 and HepG2 cells. Magnoloside B has the potential to study cancer and diabetes.
    Magnoloside B
  • HY-128129
    UT-B-IN-1 892742-76-6 99.68%
    UT-B-IN-1 (UTBINH-14) is a reversible, competitive and selective urea transporter-B (UT-B) inhibitor with IC50 values of 10 and 25 nM for human and mouse UT-B, respectively. UT-B-IN-1 shows low toxicity and high selectivity for UT-B over UT-A isoforms. UT-B-IN-1 increases urine output and reduces urine osmolality of mice. UT-B-IN-1 can be used for diuretic mechanism research.
    UT-B-IN-1
  • HY-134900
    Allyl methyl trisulfide 34135-85-8
    Allyl methyl trisulfide is a volatile organic compound and a component of garlic (Allium sativum L.) essential oil, which has antibacterial, antioxidant and antitumor activities.
    Allyl methyl trisulfide
  • HY-135783
    AT 1001 1314801-63-2 99.94%
    AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease.
    AT 1001
  • HY-137318
    BM 15766 sulfate 86621-94-5
    BM 15766 sulfate is an inhibitor of 7-dehydrocholesterol δ7-reductase and reduces plasma cholesterol levels. BM 15766 sulfate is a hypolipidemic agent.
    BM 15766 sulfate
  • HY-141487
    CLP-3094 312749-73-8 99.92%
    CLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). CLP-3094 inhibits AR transcriptional activity (IC50=4 μM). CLP-3094 is a selective, potent GPR142 antagonist.
    CLP-3094
  • HY-143227
    DK3 1187568-16-6 99.82%
    DK3 is a potent and selective estrogen-related receptor alpha (ERRα) agonist.
    DK3
  • HY-145270
    ELOVL1-IN-2 2761063-79-8 99.82%
    ELOVL1-IN-2 is an elongation of very long chain fatty acid 1 (ELOVL1) enzyme inhibitor, ELOVL1-IN-2 shows weak ELOVL1 inhibition (IC50=21 μM) and moderate potency in a primary cellular assay (HEK293 C26 IC50=6.7 μM) .
    ELOVL1-IN-2
Cat. No. Product Name / Synonyms Application Reactivity